TY - JOUR
T1 - A Systematic Review and Meta-analysis of Mobile Health Applications and Telemonitoring in Atopic Dermatitis Self-Management
AU - Cherrez-Ojeda, Ivan
AU - Robles-Velasco, Karla
AU - Osorio, María F.
AU - Ormaza Vera, Ana
AU - Sarfraz, Zouina
AU - Sarfraz, Azza
AU - Cherrez, Annia
AU - Cherrez, Sofia
AU - Sanchez Caraballo, Jorge Mario
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/7
Y1 - 2024/7
N2 - Introduction: Up to 25% of children and 5.6% of adults in the USA have atopic dermatitis (AD), with substantial impacts on quality of life. Effective control can be challenging despite therapy efforts. The emergence of information and communication technologies (ICT) in AD management prompted this study to assess its impact on self-management. We conducted a meta-analysis to assess outcomes from peer-reviewed clinical trials evaluating the effectiveness of teledermatology, mobile health (mHealth) apps, and electronic devices for managing AD. Methods: We searched PubMed, Web of Science, Scopus, and Embase for articles written in English and published until May 2023. Results: Twelve trials with 2424 participants were selected from 811 studies. A meta-analysis of 1038 individuals reported a mean difference (MD) of −1.57 [95% confidence interval (CI): −2.24, −0.91] for the Patient Oriented Eczema Measure (POEM). A meta-analysis of 495 individuals reported a Dermatology Life Quality Index (DLQI) MD of −0.59 [95% CI: −0.95, −0.23]. Despite heterogeneity (I2 = 47% and I2 = 74%), the impact was significant (P ≤ 0.001). SCORing Atopic Dermatitis (SCORAD) showed an insignificant MD of −0.12 (P = 0.91). Conclusion: mHealth applications and telemonitoring show significant improvement in patients’ quality of life (DLQI) and self-management (POEM) but no significant impact on AD severity (SCORAD).
AB - Introduction: Up to 25% of children and 5.6% of adults in the USA have atopic dermatitis (AD), with substantial impacts on quality of life. Effective control can be challenging despite therapy efforts. The emergence of information and communication technologies (ICT) in AD management prompted this study to assess its impact on self-management. We conducted a meta-analysis to assess outcomes from peer-reviewed clinical trials evaluating the effectiveness of teledermatology, mobile health (mHealth) apps, and electronic devices for managing AD. Methods: We searched PubMed, Web of Science, Scopus, and Embase for articles written in English and published until May 2023. Results: Twelve trials with 2424 participants were selected from 811 studies. A meta-analysis of 1038 individuals reported a mean difference (MD) of −1.57 [95% confidence interval (CI): −2.24, −0.91] for the Patient Oriented Eczema Measure (POEM). A meta-analysis of 495 individuals reported a Dermatology Life Quality Index (DLQI) MD of −0.59 [95% CI: −0.95, −0.23]. Despite heterogeneity (I2 = 47% and I2 = 74%), the impact was significant (P ≤ 0.001). SCORing Atopic Dermatitis (SCORAD) showed an insignificant MD of −0.12 (P = 0.91). Conclusion: mHealth applications and telemonitoring show significant improvement in patients’ quality of life (DLQI) and self-management (POEM) but no significant impact on AD severity (SCORAD).
KW - Atopic dermatitis
KW - Electronic devices
KW - Mobile apps
KW - Self-management
KW - Smart devices
KW - Teledermatology
KW - Telemonitoring
KW - mHealth applications
UR - https://www.scopus.com/pages/publications/85196671692
U2 - 10.1007/s13555-024-01213-0
DO - 10.1007/s13555-024-01213-0
M3 - Artículo de revisión
AN - SCOPUS:85196671692
SN - 2193-8210
VL - 14
SP - 1787
EP - 1798
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 7
ER -